CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Harvard Bioscience Q3 revenue rises 8%, beats estimates

By Reuters News


Overview

  • Life science tech developer's Q3 revenue grew 8% yr/yr, beating analyst expectations

  • Net loss for Q3 widened compared to prior year

  • Company reaffirmed full-year 2026 revenue growth guidance of 3%-5%


Outlook

  • Company expects Q4 revenue between $23.7 mln and $25.5 mln

  • Company sees Q4 adjusted gross margin between 59% and 61%

  • Harvard Bioscience reaffirms full-year 2026 revenue growth guidance of 3%-5%


Result Drivers

  • CHINA AND CRO SALES - Co said double-digit revenue growth to contract research organizations and customers in China drove Q3 topline increase

  • PRODUCT DEMAND - Co cited ongoing demand for organoids, respiratory, and fluidics products as supporting Q3 revenue growth

  • HIGHER EXPENSES - Higher expenses related to sales and administration contributed to wider net loss


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$22.20 mln

$21.80 mln (3 Analysts)

Q3 Adjusted Loss Per Share

Beat

$0.06

$0.17 (2 Analysts)

Q3 Net Loss

$2.62 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Harvard Bioscience Inc is $10.25, about 12.8% above its November 9 closing price of $9.09


Reuters Recommended Reads

  • Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

  • Nov 9 - Quanterix Q3 revenue rises 6.3% sequentially

  • Nov 10 - MaxCyte looks to acquire Akron Bio to expand cell therapy manufacturing; Q3 revenue rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.